May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins
S. Kawahara; Y. Hata; T. Kita; R. Arita; M. Miura; S. Nakao; Y. Mochizuki; A. Ueno; A. Hafezi-Moghadam; T. Ishibashi
Author Affiliations & Notes
  • S. Kawahara
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Y. Hata
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • T. Kita
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • R. Arita
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • M. Miura
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • S. Nakao
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Y. Mochizuki
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • A. Ueno
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • A. Hafezi-Moghadam
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • T. Ishibashi
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships  S. Kawahara, None; Y. Hata, None; T. Kita, None; R. Arita, None; M. Miura, None; S. Nakao, None; Y. Mochizuki, None; A. Ueno, None; A. Hafezi-Moghadam, None; T. Ishibashi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      S. Kawahara, Y. Hata, T. Kita, R. Arita, M. Miura, S. Nakao, Y. Mochizuki, A. Ueno, A. Hafezi-Moghadam, T. Ishibashi; Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5248.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Cicatricial contraction of preretinal proliferative membrane limits the surgical success for the treatment of proliferative vitreoretinal diseases such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). Novel pharmaceutical approaches are thus urgently needed for the management of these vision-threatening diseases. In this study, preventive effects of simvastatin, an inhibitor of HMG-CoA reductase, on the cicatricial contraction of proliferative membranes were examined.

Methods: : Using cultured bovine hyalocytes, the inhibitory effects of simvastatin on transforming growth factor (TGF)-β2-dependent phosphorylation of myosin light chain (MLC) were analyzed by Western blotting. An in vitro type I collagen gel contraction assay was performed to evaluate the inhibitory effects of simvastatin on TGF-β2-dependent collagen gel contraction. The enhancements of MLC phophorylation and collagen gel contraction by exposing human vitreous samples were also evaluated. Furthermore, an experimental model of PVR was made in rabbit eyes, and the preventive effects of intravitreal application of simvastatin on the progression of PVR were examined.

Results: : Simvastatin inhibited TGF-β2-dependent phosphorylation of MLC and collagen gel contraction in a dose- and time-dependent manner. Human vitreous samples enhanced the phosphorylation state of MLC and collagen gel contraction, and the enhancements caused by the vitreous with PDR or PVR were larger than those caused by the vitreous with non-proliferative vitreoretinal disease. Simvastatin almost completely inhibited these enhancements. Finally, simvastatin significantly prevented the progression of PVR in rabbit eyes without apparent adverse effects.

Conclusions: : These data indicated a novel therapeutic potential of simvastatin preventing cicatricial contraction of proliferative membranes in proliferative vitreoretinal diseases.

Keywords: proliferative vitreoretinopathy • drug toxicity/drug effects 
© 2008, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept